<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<?properties manuscript?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-journal-id">0213264</journal-id>
<journal-id journal-id-type="pubmed-jr-id">1117</journal-id>
<journal-id journal-id-type="nlm-ta">Biol Psychiatry</journal-id>
<journal-id journal-id-type="iso-abbrev">Biol. Psychiatry</journal-id>
<journal-title-group>
<journal-title>Biological psychiatry</journal-title>
</journal-title-group>
<issn pub-type="ppub">0006-3223</issn>
<issn pub-type="epub">1873-2402</issn>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">28137374</article-id>
<article-id pub-id-type="pmc">5513502</article-id>
<article-id pub-id-type="doi">10.1016/j.biopsych.2016.10.020</article-id>
<article-id pub-id-type="manuscript">NIHMS843184</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Maternal immune activation and autism spectrum disorder: From rodents
to nonhuman and human primates</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Careaga</surname>
<given-names>Milo</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="aff" rid="A2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Murai</surname>
<given-names>Takeshi</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="aff" rid="A3">3</xref>
<xref ref-type="aff" rid="A4">4</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Bauman</surname>
<given-names>Melissa D.</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="aff" rid="A2">2</xref>
<xref ref-type="aff" rid="A3">3</xref>
<xref ref-type="author-notes" rid="FN1">*</xref>
</contrib>
</contrib-group>
<aff id="A1">
<label>1</label>The UC Davis MIND Institute, University of California, Davis</aff>
<aff id="A2">
<label>2</label>Department of Psychiatry and Behavioral Sciences, University of
California, Davis</aff>
<aff id="A3">
<label>3</label>California National Primate Research Center, University of
California, Davis</aff>
<aff id="A4">
<label>4</label>Biomarker Group, Drug Development Research Laboratories, Sumitomo
Dainippon Pharma Co., Ltd</aff>
<author-notes>
<corresp id="FN1">Corresponding Author: <bold>Melissa D. Bauman, PhD,</bold>
Associate Professor, Department of Psychiatry &amp; Behavioral Sciences,
University of California, Davis, Mailing Address: The UC Davis MIND Institute,
Biosciences Building #1416, 2805 50<sup>th</sup> Street, Sacramento, CA
95817, <email>mdbauman@ucdavis.edu</email>, (916)-703-0377</corresp>
</author-notes>
<pub-date pub-type="nihms-submitted">
<day>18</day>
<month>4</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="epub">
<day>25</day>
<month>10</month>
<year>2016</year>
</pub-date>
<pub-date pub-type="ppub">
<day>01</day>
<month>3</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>01</day>
<month>3</month>
<year>2018</year>
</pub-date>
<volume>81</volume>
<issue>5</issue>
<fpage>391</fpage>
<lpage>401</lpage>
<!--elocation-id from pubmed: 10.1016/j.biopsych.2016.10.020-->
<abstract>
<p id="P1">A subset of women who are exposed to infection during pregnancy have an
increased risk of giving birth to a child who will later be diagnosed with a
neurodevelopmental or neuropsychiatric disorder. Although epidemiology studies
have primarily focused on the association between maternal infection and an
increased risk of offspring schizophrenia (SZ), mounting evidence indicates that
maternal infection may also increase the risk of autism spectrum disorder (ASD).
A number of factors, including genetic susceptibility, the intensity and timing
of the infection, and exposure to additional aversive postnatal events, may
influence the extent to which maternal infection alters fetal brain development
and which disease phenotype (ASD; SZ; other neurodevelopmental disorders) is
expressed. Preclinical animal models provide a test bed to systematically
evaluate the effects of maternal infection on fetal brain development, determine
the relevance to human CNS disorders, and to evaluate novel preventative and
therapeutic strategies. Maternal immune activation (MIA) models in mice, rats,
and nonhuman primates suggest that the maternal immune response is the critical
link between exposure to infection during pregnancy and subsequent changes in
brain and behavioral development of offspring. However, differences in the type,
severity, and timing of prenatal immune challenge paired with inconsistencies in
behavioral phenotyping approaches have hindered the translation of preclinical
results to human studies. Here we highlight the promises and limitations of the
MIA model as a preclinical tool to study prenatal risk factors for ASD, and
suggest specific changes to improve reproducibility and maximize translational
potential.</p>
</abstract>
<kwd-group>
<kwd>animal model</kwd>
<kwd>autism</kwd>
<kwd>schizophrenia</kwd>
<kwd>neuroimmunology</kwd>
<kwd>prenatal</kwd>
<kwd>risk factor</kwd>
</kwd-group>
</article-meta>
</front>
</article>
</pmc-articleset>